RAPT Therapeutics Investor Relations Material

RAPT Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. The company's primary focus is on discovering, developing, and commercializing oral small molecule therapies for significant unmet needs in inflammatory diseases and cancer. Utilizing a proprietary drug discovery and development engine, RAPT Therapeutics designs highly selective small molecules aimed at modulating critical immune responses. The company's pipeline includes drug candidates targeting CCR4 and other key immune pathways, with ongoing development for conditions such as atopic dermatitis and various cancers. RAPT Therapeutics is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.